Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The oral MS therapy adds the FDA rebuff to a January EU rejection; both regulatory bodies want to get a better fix on the drug's risk/benefit profile.

You may also be interested in...



Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

Merck KGaA Previews Cladribine Regulatory Revival Story At ECTRIMS

With the EMA’s review of the latest MAA for cladribine ongoing, Merck KGaA uses ECTRIMS 2016 to showcase longer-term efficacy data and a safety analysis that could lay to rest concerns about the multiple sclerosis therapy's risk of malignancy.

Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger

Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.

Related Content

Topics

UsernamePublicRestriction

Register

PS071980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel